ArticleCancer immunology, immunotherapy : CII2024

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study.

Lingzhan Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.